Travelling with Inflammatory Bowel Disease: Clinical Considerations
DOI:
https://doi.org/10.58931/cibdt.2025.3244Abstract
Key Takeaways:
• Pre-travel consultation is essential for safe and enjoyable travel. IBD patients and physicians should discuss necessary vaccinations and action plans as soon as possible.
• Preparing for travel by packing a medical kit, necessary medications and obtaining adequate travel insurance can reduce stress and mitigate problems.
• Pre-travel vaccination is an important part of the preparations for many IBD patients. Live vaccines are contraindicated in patients taking immunosuppressant medications. Expert advice from a travel medicine specialist can identify individual patient vaccinations needs.
• There are several resources available to physicians and patients alike, to empower our patients and remove many of the barriers they face when travelling.
References
Highlights, 2024 Edition. UN Tourism Madrid; [updated 2024 November, cited 25 June 2025]. Available from: https://www.e-unwto.org/doi/10.18111/9789284425808 .
Stienlauf S, Streltsin B, Meltzer E, Kopel E, Leshem E, Segal G, et al. Chronic illnesses in travelers to developing countries. Travel Med Infect Dis. 2014;12(6 Pt B):757-763. doi:10.1016/j.tmaid.2014.10.004 DOI: https://doi.org/10.1016/j.tmaid.2014.10.004
Greveson K, Shepherd T, Mulligan JP, Hamilton M, Woodward S, Norton C, et al. Travel health and pretravel preparation in the patient with inflammatory bowel disease. Frontline Gastroenterol. 2016;7(1):60–65. doi:10.1136/flgastro-2014-100548 DOI: https://doi.org/10.1136/flgastro-2014-100548
Philip V, Soubieres A, Poullis A. Health concerns associated with travelling with inflammatory bowel disease (IBD): a questionnaire survey. Clin Med (Lond). 2018;18(4):288–292. doi:10.7861/clinmedicine.18-4-288 DOI: https://doi.org/10.7861/clinmedicine.18-4-288
Aluzaite K, Greveson K, Ben-Horin S, Leong R, Haj O, Schultz M. Barriers to international travel in inflammatory bowel disease patients. J travel Med. 2021;28(1):taaa197. doi:10.1093/jtm/taaa197 DOI: https://doi.org/10.1093/jtm/taaa197
Ben-Horin S, Bujanover Y, Goldstein S, Nadler M, Lang A, Kopylov U, et al. Travel-associated health risks for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10(2):160–165,165.e161. doi:10.1016/j.cgh.2011.10.025 DOI: https://doi.org/10.1016/j.cgh.2011.10.025
Park J, Yoon H, Shin CM, Park YS, Kim N, Lee DH. Clinical factors to predict flare-up in patients with inflammatory bowel disease during international air travel: a prospective study. PLoS One. 2022;17(1):e0262571. doi:10.1371/journal.pone.0262571 DOI: https://doi.org/10.1371/journal.pone.0262571
Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohn’s Colitis. 2021;15(6):879–913. doi:10.1093/ecco-jcc/jjab052 DOI: https://doi.org/10.1093/ecco-jcc/jjab052
Chan W, Shim HH, Ng SC, Liu J, Inglis C, Greveson K, et al. A global survey of gastroenterologists’ travel advice to patients with inflammatory bowel disease on immunosuppressive agents and management of those visiting tuberculosis-endemic areas. J Crohns Colitis. 2018;12(11):1261–1269. doi:10.1093/ecco-jcc/jjy110 DOI: https://doi.org/10.1093/ecco-jcc/jjy110
Mushtaq A. Supporting travel in patients with inflammatory bowel disease. The Lancet Gastroenterology & Hepatology. 2019;4(7):499–500. doi:10.1016/S2468-1253(19)30154-2 DOI: https://doi.org/10.1016/S2468-1253(19)30154-2
Russel MG, Ryan BM, Dagnelie PC, de Rooij M, Sijbrandij J, Feleus A, et al. Insurance problems among inflammatory bowel disease patients: results of a Dutch population based study. Gut. 2003;52(3):358–362. doi:10.1136/gut.52.3.358 DOI: https://doi.org/10.1136/gut.52.3.358
Kakoullis L, Steffen R, Osterhaus A, Goeijenbier M, Rao SR, Koiso S, et al. Influenza: seasonality and travel-related considerations. J Travel Med. 2023;30(5):taad102. doi:10.1093/jtm/taad102 DOI: https://doi.org/10.1093/jtm/taad102
Public Health Agency of Canada. Immunization of travellers:Canadian Immunization Guide. Ottawa: Government of Canada 2025. [updated 29 May 2025, cited 2025 June 2]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-9-immunization-travellers.html.
Freedman DO, Chen LH, Kozarsky PE. Medical Considerations before International Travel. N Engl J Med. 2016;375(3):247–260. doi:10.1056/NEJMra1508815 DOI: https://doi.org/10.1056/NEJMra1508815
Soonawala D, van Eggermond AM, Fidder H, Visser LG. Pretravel preparation and travel-related morbidity in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(11):2079–2085. doi:10.1002/ibd.22903 DOI: https://doi.org/10.1002/ibd.22903
Connor BA, Leung DT. CDC Yellow Book: Health Information for International Travel. In: CDC Yellow Book 2026. [updaded 23 April 2025, accessed 25 June 2025]. Available from: https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html.
Mala W, Kotepui KU, Masangkay FR, Wangdi K, Wilairatana P, Kotepui M. Evidence of pathogens associated with travelers’ diarrhea in Thailand: a systematic review. Trop Dis Travel Med Vaccines. 2025;11(1):8. doi:10.1186/s40794-024-00243-y DOI: https://doi.org/10.1186/s40794-024-00243-y
McKerrow Johnson I, Shatzel J, Olson S, Kohl T, Hamilton A, DeLoughery TG. Travel-associated venous thromboembolism. Wilderness Environ Med. 2022;33(2):169–178. doi:10.1016/j.wem.2022.02.004 DOI: https://doi.org/10.1016/j.wem.2022.02.004
Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med. 2009;151(3):180–190. doi:10.7326/0003-4819-151-3-200908040-00129 DOI: https://doi.org/10.7326/0003-4819-151-3-200908040-00129
Watson HG, Baglin TP. Guidelines on travel-related venous thrombosis. Br J Haematol. 2011;152(1):31–34. doi:10.1111/j.1365-2141.2010.08408.x DOI: https://doi.org/10.1111/j.1365-2141.2010.08408.x
World Health Organisation. Global tuberculosis report 2021. World Health Organization 2021. [updated 14 October 2021, cited 25 June 2025]. Available from: https://www.who.int/publications/i/item/9789240037021#:~:text=Each%20year%2C%20the%20WHO%20Global%20TB%20Report%20provides,context%20of%20global%20TB%20commitments%2C%20strategies%20and%20targets.
Fehily SR, Al-Ani AH, Abdelmalak J, Rentch C, Zhang E, Denholm JT, et al. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther. 2022;56(1):6–27. doi:10.1111/apt.16952 DOI: https://doi.org/10.1111/apt.16952
Hofland R, Verhagen M, Huisman R, Bossink A. Sa1227 Should screening for latent tuberculosis infection be repeated after travel to tuberculosis endemic areas in patients treated with TNF-alpha inhibitor therapy? Gastroenterology. 2012;142(5):S–249. doi:10.1016/S0016-5085(12)60934-2 DOI: https://doi.org/10.1016/S0016-5085(12)60934-2
Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14(6):503–509. doi:10.1016/j.autrev.2015.01.011 DOI: https://doi.org/10.1016/j.autrev.2015.01.011
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Canadian IBD Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
